Taro Masunaga

Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS)

Hideki Hirabayashi, Toshiya Takahashi, Jiro Fujisaki et al. · Journal of Controlled Release · 2001 · 75 citations

Bone Disease, Pharmaceutical Science, Bone-specific Delivery +9

Stromal Cell–Derived Factor-1 and CXCR4 Interaction Is Critical for Development of Transplant Arteriosclerosis

Hideyasu Sakihama, Taro Masunaga, Kenichiro Yamashita et al. · Circulation · 2004 · 61 citations · Full text

FR255734, a Humanized, Fc-Silent, Anti-CD28 Antibody, Improves Psoriasis in the SCID Mouse-Psoriasis Xenograft Model

S. P. Raychaudhuri, Smriti Kundu‐Raychaudhuri, Kouichi Tamura et al. · Journal of Investigative Dermatology · 2008 · 37 citations · Full text

Autoimmune Disease, Anti-cd28 Antibody, Cutaneous Biology +7

Enhancement of T‐cell‐mediated anti‐tumour immunity via the ectopically expressed glucocorticoid‐induced tumour necrosis factor receptor‐related receptor ligand (GITRL) on tumours

Jinhua Piao, Yosuke Kamimura, Hideyuki Iwai et al. · Immunology · 2008 · 37 citations · Full text

Tumour Necrosis Factor, Immunology, Immune Regulation +17

Long-term acceptance of rat cardiac allografts on the basis of adenovirus mediated CD40Ig plus CTLA4Ig gene therapies

Kenichiro Yamashita, Taro Masunaga, Naoyuki Yanagida et al. · Transplantation · 2003 · 35 citations